Acute Myelogenous Leukemia
Acute Myelogenous (or Myeloid) Leukemia (AML), is a rare disease of the hematopoietic system (blood forming system) in the bone marrow. It appears in 1.2% of all cancers, and strikes all ages.
The disease is caused by proliferation of white blood cells. There are many types of AML which are categorized by genetic and hematology laboratory parameters. Different types require different treatment regimens and carry different prognoses. If too many white cells are found in the bloodstream, a diagnosis of AML should be considered. Normally humans have 4,000 to 8,000 leukocytes. These numbers can increase to 20,000 or more if the patient has an infection. When the number of leukocytes is more than 15,000 without signs and symptoms of an infection, leukemia should be considered.
In Acute Myeloid Leukemia there is usually a sudden rise of white blood cells to over 25,000. When looked at under the microscope lens, they are seen to be atypical, with large cells and prominent nuclei, i.e., immature embryonic cells also known as blasts. The symptoms of AML are associated with the replacement of normal white and red blood cells with these immature blast cells in the bone marrow and in peripheral blood. As a result of this replacement, patients develop a tendency to bleed easily, such as when brushing their teeth. They also tend to develop infections which the body cannot withstand.
Treatment requires rapid diagnosis, and blood and blood product transfusions, as well as chemotherapy. In children, effective treatment is more achievable than in adults. Failure to diagnose this condition in a child can lead to loss of an opportunity to induce a remission leading to death.



